Intrastent restenosis is a common complication after intracranial and extracranial arterial stenting and an important cause of recurrent ischemic stroke. Studies have shown that Tongxinluo capsule can protect the injured inner cells, reduce inflammation, inhibit the proliferation and migration of smooth muscle cells, inhibit the proliferation of plaque and nourish blood vessels, and resist arteriosclerosis. This study was a multicenter prospective randomized controlled clinical trial. Participants with intracranial and extracranial atherosclerotic stenosis who successfully underwent arterial stenting were included in the study, and were divided into Tongxinluo test group and control group. Clinical and related auxiliary examination data were collected at each follow-up point. To explore the effectiveness and potential mechanism of Tongxinluo capsule in preventing and treating restenosis after intracranial and external arterial stenting, and to provide reference for expanding clinical use of traditional Chinese medicine.

开始日期2023-10-01

申办/合作机构

山东第一医科大学第一附属医院（山东省千佛山医院、山东省牙病防治指导中心）

NCT06061692

/ Not yet recruiting临床4期IIT

Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study (TOPS-CSVD)

Cerebral small vessel disease is a series of clinical, imaging and pathological syndromes caused by various etiologies affecting the arteries, capillaries, venules in the brain. The common causes of cerebral small vessel disease include arteriolosclerosis, cerebral amyloid angiopathy, hereditary cerebral small vessel disease, inflammation-and immune-mediated small vessel disease, venous collagen disease and other small vessel diseases. Of these, age-and hypertension-related cerebral small vessel disease and amyloidosis cerebral small vessel disease are the most common types. The pathophysiological mechanism and clinical manifestations of cerebral small vessel disease are complex. One-fifth of ischemic strokes and the vast majority of nontraumatic parenchymal hemorrhages are due to cerebral small vessel disease. In addition to stroke, patients with cerebral small vessel disease are more often characterized by chronic progressive neurological impairment, which is an important cause of cognitive decline and functional disability in the elderly, and has become one of the important public health problems affecting the quality of life of the elderly.
Focusing on cognitive impairment-related diseases, a large number of clinical studies have shown that Tongxinluo capsule has a dual neurovascular protective effect, which can increase the Mini-Mental State Examination (MMSE) score and activities of daily living (ADL) score of patients with lacunar cerebral infarction combined with vascular cognitive impairment, reduce fibrinogen (FIB) concentration, improve whole blood viscosity, improve blood viscosity and FIB level, improve activities of daily living and accelerate intellectual recovery in patients with VD; It can also reduce the levels of ET-1 and homocysteine in AD patients, reduce the whole blood viscosity and thus improve the microcirculation in the elderly, increase cerebral blood flow, increase the scores of MMSE and ADL, improve the intelligence of patients, improve memory disorders and language disorders. Meta-analysis of 3458 patients in 40 published clinical literatures of Tongxinluo capsule both domestically and internationally confirmed that Tongxinluo capsule had the effect of promoting the recovery of neurological function, and was safe without adverse reactions.
This project is a randomized, double-blind, placebo-controlled multicenter clinical study to investigate the clinical efficacy and safety of Tongxinluo capsule in the treatment of cerebral small vessel disease. A total of 1052 subjects who met the subject screening criteria are planned to be enrolled, with 526 patients in the test group and 526 patients in the placebo group.
The study is conducted using a central randomization method. For the patients who met the inclusion criteria after examination, they are logged into the Interactive Web Response System by their site, entered the relevant information, and randomized and assigned drugs automatically by the central server according to the ratio of 1:1. Once enrolled, all patients receive the study drug (Tongxinluo or placebo) at 4 capsules/tid for up to 12 months. The study is planned to be conducted at approximately 50 centers across the country using central randomized competing enrollment.

开始日期2023-10-01

申办/合作机构

复旦大学

ChiCTR2100054466

/ RecruitingN/AIIT

Multicenter, prospective study of Tongxinluo in the treatment of acute ST-segment elevation myocardial infarction

开始日期2021-12-23

申办/合作机构

河北以岭医院

100 项与通心络相关的临床结果

登录后查看更多信息

100 项与通心络相关的转化医学

登录后查看更多信息

100 项与通心络相关的专利（医药）

登录后查看更多信息

197

项与通心络相关的文献（医药）

2024-09-01·PHYTOMEDICINE

Chinese patent medicine Tongxinluo: A review on chemical constituents, pharmacological activities, quality control, and clinical applications

Review

作者: Shi, Yajun ; Guo, Dongyan ; Chen, Qin ; Sun, Jing ; Zhang, Xiaofei ; Luan, Fei ; Zou, Junbo

BACKGROUND:

Cardiovascular and cerebrovascular disease (CCVD) is the leading cause of morbidity and mortality worldwide, imposing a significant economic burden on individuals and societies. For the past few years, Traditional Chinese Medicine (TCM) has attracted much attention due to its advantages such as fewer side effects in the treatment of CCVD. TXL has shown great promise in the treatment of CCVD.

PURPOSE:

This paper aims to provide a comprehensive introduction to TXL, covering its chemical constituents, quality control, pharmacological properties, adverse reactions, and clinical applications through an extensive search of relevant electronic databases while discussing its current challenges and provides opinions for future study.

METHODS:

The following electronic databases were searched up to 2023: "TXL", "CCVD", "Chemical constituents", "Quality control" and "Pharmacological properties" were entered as keywords in PubMed, Web of Science, Google Scholar and China National Knowledge Infrastructure Database and WANFANG DATA databases. The PRISMA guidelines were followed in this review process.

RESULTS:

Studies have confirmed that TXL is effective in treating patients with CCVD and has fewer adverse effects. The aim of this review is to explore TXL anti-CCVD effects in relation to oxidative stress, lipid metabolism and enhanced cardiac function. This review also provides additional information on safety issues.

CONCLUSION:

TXL plays a key role in the treatment of CCVD by regulating various pathways such as lipid metabolism, oxidative stress and inflammation. However, further clinical trials and animal experiments are needed to provide more evidence and recommendations for its clinical application. This article provides an overview of TXL research to inform and inspire future studies.

2024-07-01·Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

[Network Meta-analysis of Chinese patent medicines in treatment of chronic pulmonary heart disease].

Article

作者: Yu, Rui ; Wang, Xin-Lu ; Li, Xue ; Peng, Guang-Cao ; Zhu, Ming-Jun ; Wu, Wen-Jun ; Wei, Jing-Jing ; Zhang, Chi-Dao

Network Meta-analysis was performed to compare the efficacy and safety of Chinese patent medicines in treating chronic pulmonary heart disease. CNKI, VIP, Wanfang, SinoMed, PubMed, Web of Science, EMbase, and Cochrane Library were searched for randomized controlled trial(RCT) of treating chronic pulmonary heart disease with Chinese patent medicines with the time interval from inception to December 2023. The Cochrane risk-of-bias tool was used for quality assessment of the included articles. RevMan 5.4 and Stata 17.0 were employed to establish the risk of bias map and perform the network Meta-analysis, respectively. Ultimately, a total of 95 RCTs involving 8 787 cases and 11 different Chinese patent medicines were included. Network Meta-analysis yielded the following results based on the surface under the cumulative ranking curve(SUCRA).(1)In terms of cardiac function improves clinical total effective rate, SUCRA the top three were Wenxin Granules + conventional western medicine, Tongxinluo Capsules + conventional western medicine, and Qishen Yiqi Dropping Pills + conventional western medicine.(2)For improving forced expiratory volume in the first se-cond(FEV1), SUCRA the top three were Danting Feixin Granules + conventional western medicine, Tongxinluo Capsules + conventional western medicine, and Bufei Huoxue Capsules + conventional western medicine.(3)Regarding increasing the FEV1/forced vital capacity(FVC%) value, SUCRA the top three were Qili Qiangxin Capsules + conventional western medicine, Shexiang Baoxin Pills + conventional western medicine, and Qishen Yiqi Dropping Pills + conventional western medicine.(4)In terms of increasing the partial pressure of oxygen(PaO_2), SUCRA the top three were Qili Qiangxin Capsules + conventional western medicine, Qishen Yiqi Dropping Pills + conventional western medicine, and Shexiang Baoxin Pills + conventional western medicine.(5)In terms of reducing the partial pressure of carbon dioxide(PaCO_2), SUCRA the top three were Tongxinluo Capsules + conventional western medicine, Qishen Yiqi Dropping Pills + conventional western medicine, and Shexiang Baoxin Pills + conventional western medicine.(6)In terms of increasing left ventricular ejection fraction(LVEF), SUCRA the top three were Bufei Huoxue Capsules + conventional western medicine, Qishen Yiqi Dropping Pills + conventional western medicine, and Shexiang Baoxin Pills + conventional western medicine.(7)In terms of decreasing brain natriu-retic peptide(BNP), SUCRA the top three were Compound Danshen Dropping Pills + conventional western medicine, Qili Qiangxin Capsules + conventional western medicine, and Tongxinluo Capsules + conventional western medicine.(8)In terms of improving the hematocrit level, SUCRA the top three were Qishen Yiqi Dropping Pills + conventional western medicine, Compound Danshen Dropping Pills + conventional western medicine, and Tongxinluo Capsules + conventional western medicine. In terms of safety, 26 RCTs reported adverse reactions, which primarily involved the circulatory and digestive systems. The combination of Chinese patent medicines with conventional western medicine has demonstrated enhanced therapeutic effects on chronic pulmonary heart disease. However, due to the varying quality and sample sizes of included studies and the absence of direct comparisons between Chinese patent medicines, the conclusions should be further validated by multicenter studies with larger sample sizes and higher methodological rigor.

2024-07-01·Heliyon

Tongxinluo capsule as a multi-functional traditional Chinese medicine in treating cardiovascular disease: A review of components, pharmacological mechanisms, and clinical applications

Review

作者: He, Yanling ; Zhang, Dan ; Wei, Cong ; Wang, Xiaoqi ; Xin, Jingjing ; Lu, Xuan ; Han, Ningxin ; Wang, Tongxing ; Jia, Zhenhua ; Hou, Bin

Cardiovascular diseases (CVDs) are one of the most significant diseases that pose a threat to human health. The innovative traditional Chinese medicine Tongxinluo Capsule, developed under the guidance of the theory of traditional Chinese medicine, has good clinical efficacy in various cardiovascular diseases, this medicine has effects such as blood protection, vascular protection, myocardial protection, stabilizing vulnerable plaques, and vasodilation. However, CVDs are a multifactorial disease, and their underlying mechanisms are not fully understood. Therefore, exploring the mechanism of action and clinical application of Tongxinluo Capsule in the treatment of various cardiovascular diseases is beneficial for exerting its therapeutic effect from multiple components, targets, and pathways. At the same time, it provides broader treatment ideas for other difficult to treat diseases in the cardiovascular event chain, and has significant theoretical and clinical significance for improving the treatment of cardiovascular diseases with traditional Chinese medicine.

项与通心络相关的新闻（医药）

2024-12-09

·米内网

这家中药企业厉害了！手握22个独家品种，5大超10亿品种亮眼，14款1类新药畜力

精彩内容近日，以岭药业的中药1.1类新药通络明目胶囊进保、辛伐他汀片在美国获批上市。今年以来，公司已有2款1类新药申报NDA、2款1类新药申报IND。以岭药业坚持创新驱动，拥有22个中药独家品种，领跑感冒、心脑血管、糖尿病中成药市场；研发管线迎来收获期，14款1类新药在研，6款处于NDA或Ⅲ期临床阶段，上市可期。手握22个独家品种！5大超10亿品种亮眼 11月28日，国家医保局发布2024版国家医保药品目录调整情况，以岭药业的独家产品通络明目胶囊通过了医保谈判，首次被纳入国家医保目录。该药医保支付标准为2.17元（0.4g/粒），限2型糖尿病视网膜病变单纯性型。中药1.1类新药通络明目胶囊于2023年10月19日获批上市，具有化瘀通络、益气养阴、止血明目之功效，用于2型糖尿病引起的中度非增殖性糖尿病视网膜病变血瘀络阻、气阴两虚证所致的眼底点片状出血、目睛干涩等相关症状。该药是公司第11个进入国家医保目录的独家专利中药产品。以岭药业中药产品覆盖心脑血管、呼吸系统、肿瘤、糖尿病、神经系统、泌尿系统等重大疾病领域，代表品种有通心络胶囊、参松养心胶囊、芪苈强心胶囊、连花清瘟胶囊、津力达颗粒等。目前，公司拥有中成药生产批件49个，其中有22个中药独家品种、14款专利中药。以岭药业独家品种情况（含独家剂型品种） 5款专利中药参松养心胶囊、通心络胶囊、连花清瘟颗粒、芪苈强心胶囊、连花清瘟胶囊2023年在中国三大终端六大市场（统计范围详见本文末）销售额均超过10亿元，3款专利中药津力达颗粒、连花清咳片、夏荔芪胶囊销售额均超过1亿元。凭借通心络胶囊、参松养心胶囊和芪苈强心胶囊以及连花清瘟胶囊/颗粒、连花清咳片、津力达颗粒等专利中药，以岭药业已在感冒、心脑血管、糖尿病中药领域处于领先地位。米内网数据显示，2024H1中国三大终端六大市场感冒中成药、心脑血管疾病中成药、糖尿病中成药销售额TOP10一级集团中，以岭药业均排名第二。研发费用5.72亿元，1类新药抢攻200亿市场作为国内中药创新药龙头企业，以岭药业始终将科技创新视为企业发展的核心竞争力，近年来坚持研发投入，2023年研发费用8.53亿元，2024年前三季度研发费用5.72亿元。在A股中药企业2024年前三季度研发费用排名中，以岭药业以5.72亿元蝉联第二。 2024年至今，以岭药业已有2款1类新药柴黄利胆胶囊、苯胺洛芬注射液提交上市申请，以及2款1类新药连花御屏颗粒、G201-Na胶囊提交IND申请。柴黄利胆胶囊、苯胺洛芬注射液有望于2025年内获批上市。柴黄利胆胶囊具有清热利湿、疏肝利胆、和胃止痛之功效，用于慢性胆囊炎肝胆湿热、胃失和降证。米内网数据显示，2023年中国三大终端六大市场胆道中成药销售额超过10亿元，同比增长4.80%。连花御屏颗粒是基于玉屏风散、桂枝汤及银翘散化裁而成治疗感冒气虚证的中药新药，具有益气固卫、祛风解毒之功效，适用于感冒气虚证。米内网数据显示，2023年中国三大终端六大市场感冒中成药销售额超过210亿元，2024年上半年其销售额超过100亿元。中国三大终端六大市场感冒中成药销售情况（单位：万元）来源：米内网格局数据库苯胺洛芬注射液属于芳基烷酸类镇痛抗炎药，可以抑制前列腺素合成，通过阻断炎症介质发挥镇痛抗炎作用，拟用于成人手术后轻至中度疼痛，与阿片类镇痛药联合用于治疗术后中至重度疼痛。米内网数据显示，2023年中国三大终端六大市场止痛药销售额超过200亿元。中国三大终端六大市场止痛药销售情况（单位：万元）来源：米内网格局数据库 G201-Na胶囊为小分子促性腺激素释放激素（GnRH）受体拮抗剂，适应症为辅助生殖，用于控制性超促排卵治疗的患者，防止提前排卵。此前，该药2项适应症“需要雄激素去势治疗的前列腺癌药物”、“子宫肌瘤”的临床试验申请已获得批准，均处于Ⅰ期临床阶段。 15款新药在研，6款1类新药上市可期经过多年耕耘，以岭药业创新药管线逐步迎来收获期，近年来公司保持每年均有一款中药1.1类新药申报上市的态势。自2021年以来，公司相继提交了4款中药创新药苏夏解郁除烦胶囊、芪黄明目胶囊、辛芪通鼻片、柴黄利胆胶囊的上市申请。在新药研发方面，目前以岭药业有15款新药处于申报临床及以上研究阶段，包括8款中药1.1类新药、一款中药2类改良型新药、5款化药1类新药及一款生物药1类新药，涉及呼吸系统、风湿免疫系统、消化系统、神经系统、肿瘤、心血管、五官科及儿科等疾病领域。以岭药业主要在研新药 14款1类新药中，辛芪通鼻片（治疗持续性变应性鼻炎）、柴黄利胆胶囊（治疗慢性胆囊炎）、苯胺洛芬注射液（治疗术后疼痛）上市申请在审中，有望于2025年内获批上市；XY0206片（治疗急性髓性白血病）、小儿连花清感颗粒（治疗儿童感冒）、络痹通片（治疗类风湿性关节炎）已处于Ⅲ期临床研究阶段，上市可期。在仿制药业务方面，以岭药业有3个新注册分类品种他达拉非片、盐酸溴己新注射液、盐酸伐昔洛韦片上市申请在审中，获批生产后将视同通过一致性评价。此外，公司向美国FDA注册申报的ANDA产品辛伐他汀片于近日获得批准，已累计拥有13个美国ANDA产品的批文。资料来源：米内网数据库、公司公告注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

临床申请临床3期专利到期

2024-11-30

·思齐俱乐部

内服中成药卖了超1000亿元

内服中成药涵盖心脑血管中成药、呼吸系统中成药、泌尿系统中成药、消化系统中成药、骨骼肌肉系统中成药等13个治疗大类，市场规模庞大。数据显示，2024上半年内服中成药在中国公立医疗机构终端的销售额超过1000亿元，不少品种近年来的销售额表现亮眼，包括参松养心胶囊、通心络胶囊、连花清瘟颗粒、芪苈强心胶囊、苏黄止咳胶囊、蓝芩口服液、小儿豉翘清热颗粒、蒲地蓝消炎口服液、脑心通胶囊、复方丹参滴丸、麝香保心丸、银丹心脑通软胶囊、乌灵胶囊等。从销售额增速看，9个内服中成药销售额逆势上涨，且济川药业的小儿豉翘清热颗粒、贵州百灵的银丹心脑通软胶囊、北京北大维信的血脂康胶囊这3个品种销售额均涨超10%。其中，济川药业的小儿豉翘清热颗粒是一款儿童专用药，国家医保产品，目前仅有济川药业集团生产，其具有疏风解表、清热导滞等功效，主要用于小儿风热感冒夹滞证。近年来，该品种在中国公立医疗机构终端的销售额持续增长，2023年接近20亿元，2024年有望再创新高，其在儿科中成药产品中的市场地位也在不断提高。不过，该品种专利截止2025年到期也引发投资者的关注，对此，济川药业曾在互动平台上回答表示，公司将继续做好现有产品的二次开发以及市场推广工作，同时公司将秉承自主研发和外延式扩张双驱动的战略，进一步丰富公司的产品线，夯实公司持续发展的基础。贵州百灵的银丹心脑通软胶囊是国家基药目录产品和国家医保目录乙类产品。功能主治为活血化瘀、行气止痛，消食化滞。用于气滞血瘀引起的胸痹，症见胸痛、胸闷，气短，心悸等；冠心病心绞痛，高脂血症、脑动脉硬化，中风、中风后遗症见上述症状者。数据显示，银丹心脑通软胶囊近年来在中国公立医疗机构终端的销售额逐年增长，2020年成功突破10亿元，2023年超过14亿元，2024上半年又以约12%的增速继续增长。北京北大维信的血脂康胶囊则为全国医保甲类、全国基药品种，具有化浊降脂、活血化瘀、健脾消食的功效，用于痰阻血瘀所致的高脂血症，症见气短、乏力、头晕、头痛、胸闷、腹胀、食少纳呆等。数据显示，近年来，血脂康胶囊在中国公立医疗机构终端的销售额逐年上涨，2023年超过10亿元，2024年有望再创新高，市场地位也不断攀升。值得一提的是，北大维信的血脂康胶囊还在加速出海的步伐，2023年6月，血脂康胶囊在乌兹别克斯坦获批上市；当年的第六届中国国际进口博览会上，北大维信与阿斯利康巴西、巴西Herbarium公司签署合作备忘录，三方共同致力于将治疗高脂血症的中成药血脂康引进巴西市场，助推这一中国创新成果在巴西的注册和商业化推广等。据悉，公司方面还在进一步加强血脂康在全球市场的开发与合作，助推创新中成药的国际化进程。来源：制药网商务合作 130 6172 3098 zakk.cui@siqibest.com 点击阅读原文了解更多

专利到期上市批准

2024-11-22

·赛柏蓝

中成药销售Top 20：以岭、扬子江、天士力...

编者按：本文来自米内网，作者玲珑；赛柏蓝转载，编辑相宜数据显示，2024上半年中国公立医疗机构终端内服中成药销售规模超过1000亿元。 01 千亿市场心脑血管中成药称王鲁南制药、贵州三力亮了内服用药是中成药的主要用药途径。数据显示，近年来在中国公立医疗机构终端中成药用药途径中，内服用药占比均超过70%。近年来，内服中成药在中国公立医疗机构终端的销售额均超过1800亿元，在实现连续三年的正增长后，2024上半年出现略微下滑，其销售额超过1000亿元，同比下滑约1.4%。近年来中国公立医疗机构终端内服中成药销售情况（单位：万元）从治疗领域看，内服中成药涵盖13个治疗大类，心脑血管中成药“称王”，近年来占比均超过24%；呼吸系统中成药紧接其后，近年来占比均超过15%；泌尿系统中成药、消化系统中成药、骨骼肌肉系统中成药位列第三、第四、第五，2024上半年占比均超过9%。 2024H1中国公立医疗机构终端内服中成药大类格局在TOP20集团中，以岭药业、步长制药、国药集团、扬子江药业、济川药业依次位列前五；从销售额增速看，鲁南制药、贵州三力制药逆势涨超10%，其中鲁南制药实现了8连涨（2017-2024上半年）。 2024H1中国公立医疗机构终端内服中成药TOP5集团 02 TOP20产品出炉 3个独家品种逆势大涨内服中成药TOP20产品中，复方丹参滴丸蝉联榜首，苏黄止咳胶囊紧接其后，脑心通胶囊位居第三；20个产品中有9个2024上半年的销售额达10亿元以上，其中TOP3产品均超14亿元。 2024H1中国公立医疗机构终端内服中成药TOP20产品 20个中成药中有18个为独家品种（含独家剂型），包括以岭药业的参松养心胶囊、通心络胶囊、连花清瘟颗粒及芪苈强心胶囊，扬子江药业的苏黄止咳胶囊及蓝芩口服液，济川药业的小儿豉翘清热颗粒及蒲地蓝消炎口服液，步长制药的脑心通胶囊及稳心颗粒，天士力医药的复方丹参滴丸，上海和黄药业的麝香保心丸，贵州百灵的银丹心脑通软胶囊，佐力药业的乌灵胶囊等。从销售额增速看，9个中成药逆势上涨，济川药业的小儿豉翘清热颗粒、贵州百灵的银丹心脑通软胶囊、北京北大维信的血脂康胶囊均涨超10%，排位较2023年分别提升5个、2个、5个位次，其中北京北大维信的血脂康胶囊首次上榜内服中成药TOP20产品。小儿豉翘清热颗粒是济川药业儿科产品线的代表品种，具有疏风解表、清热导滞等功效，主要用于小儿风热感冒夹滞证。近年来，小儿豉翘清热颗粒在中国公立医疗机构终端的销售额持续增长，2023年接近20亿元，2024年有望再创新高。在儿科中成药产品排名中，小儿豉翘清热颗粒近年来蝉联榜首，市场份额由2019年的约16%提升至2024上半年的约20%。近年来中国公立医疗机构终端小儿豉翘清热颗粒销售情况（单位：万元）贵州百灵的银丹心脑通软胶囊为全国医保乙类、全国基药品种，具有活血化瘀、行气止痛、消食化滞的功效，适用于气滞血瘀引起的胸痹，症见胸痛，胸闷，气短，心悸等。该产品近年来在中国公立医疗机构终端的销售额逐年上涨，2020年首次突破10亿元，2023年超过14亿元，2024上半年以约12%的增速继续放量。近年来中国公立医疗机构终端银丹心脑通软胶囊销售情况（单位：万元）北京北大维信的血脂康胶囊为全国医保甲类、全国基药品种，具有化浊降脂、活血化瘀、健脾消食的功效，用于痰阻血瘀所致的高脂血症，症见气短、乏力、头晕、头痛、胸闷、腹胀、食少纳呆等。近年来血脂康胶囊在中国公立医疗机构终端的销售额逐年上涨，2023年超过10亿元，2024年有望再创新高。在降脂中成药产品排名中，血脂康胶囊近年来稳居首位，市场份额由2019年的37%提升至2024上半年的约56%。近年来中国公立医疗机构终端血脂康胶囊销售情况（单位：万元） 03 中药企业业绩分化方盛、康恩贝、太极等加码研发中成药市场的承压也体现在企业的业绩上。日前，A股医药企业2024年三季报已披露完毕，中药板块72家上市企业总营收超过2600亿元，利润总额超过280亿元，与去年同期相比均有下滑。其中，仅24家企业营业收入实现同比增长，27家企业归母净利润实现同比增长，营收、净利润双增长的企业仅有16家（不含亏损企业），占比仅约22%。近年来，中药企业面临着系列宏观因素的挑战，中成药集采降价、医保政策调整等政策因素导致部分企业盈利空间受到一定程度的压缩，中药材价格的持续上涨也让众多企业面临成本上升的压力，此外还有市场需求的变化、消费市场的不景气等等，共同构成了中药企业业绩承压的原因。当然，也有一批中药企业凭借自身的核心竞争力和市场策略展现出强大的活力与韧性。2024前三季度，云南白药、白云山、华润三九、片仔癀、济川药业、同仁堂、东阿阿胶7家企业净利润超过10亿元；此外，片仔癀、东阿阿胶、羚锐制药、佐力药业、贵州三力、方盛制药、莱茵生物、华森制药8家企业的营收、净利润均实现两位数增长。 2024前三季度营利双增的中药企业在复杂多变的市场环境和政策调整挑战下，创新转型也将成为中药行业发展的核心旋律，同时也是中药企业摆脱经营困境、实现突破的重要策略。2024前三季度，72家中药企业研发费用合计67亿元，与去年同期相比增长1.77%。其中，有17家企业研发费用超过1亿元，白云山、以岭药业、天士力、华润三九、康缘药业依次位列前五，从研发费用占营收比重看，康缘药业超过15%，上海凯宝超过9%，以岭药业、天士力超过8%。 2024前三季度研发费用超1亿元的中药企业来源：公司公告，米内网整理 END 内容沟通：郑瑶（13810174402）左下角「关注账号」，右下角「在看」，防止失联

申请上市

100 项与通心络相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心律失常	肯尼亚	石家庄以岭药业股份有限公司	2023-06-27
心血管疾病	肯尼亚	石家庄以岭药业股份有限公司	2023-06-27
脑血管疾病	肯尼亚	石家庄以岭药业股份有限公司	2023-06-27
慢性心力衰竭	肯尼亚	石家庄以岭药业股份有限公司	2023-06-27
心绞痛	中国	石家庄以岭药业股份有限公司	1998-01-01
冠心病	中国	石家庄以岭药业股份有限公司	1998-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01919671 (Pubmed 1 \| Pubmed 2 \| JAMA Netw Open 1 \| JAMA Netw Open 2) 人工标引	临床4期	急性缺血性卒中	-	Tongxinluo	蓋鬱夢鏇觸齋鹹糧範遞(網獵艱獵鬱憲選範繭遞) = 範築艱繭糧壓選簾糧顧齋窪糧膚蓋衊餘願構窪 (築糧選鹽淵築積夢襯選 )	积极	2024-09-26
				Placebo	蓋鬱夢鏇觸齋鹹糧範遞(網獵艱獵鬱憲選範繭遞) = 夢鹹蓋鑰艱繭鬱鹹繭淵齋窪糧膚蓋衊餘願構窪 (築糧選鹽淵築積夢襯選 )
NCT03792035 (CTS-AMI, Pubmed \| JAMA)	临床3期	急性心肌梗塞	3,797	Tongxinluo	鹽憲鬱觸憲壓鹹窪獵窪(選選製築顧壓鏇艱鏇網) = 淵淵獵淵鑰鹽壓醖築鏇窪窪構獵繭積選願獵糧 (醖製窪艱齋繭夢夢製鹹 ) 更多	积极	2023-10-24
				Placebo	鹽憲鬱觸憲壓鹹窪獵窪(選選製築顧壓鏇艱鏇網) = 鬱願壓齋觸鏇積齋餘艱窪窪構獵繭積選願獵糧 (醖製窪艱齋繭夢夢製鹹 ) 更多